Supporting screening for suspected left ventricular dysfunction using ECG CEO Kim Joong-hee: “First gateway to enter the U.S. market” … pursuing adoption by local medical institutions
Promotional image for “ECG Buddy-LVD” created using Claude. Photo courtesy of ALP
Medical artificial intelligence (AI) company ALP announced that its AI electrocardiogram (ECG) analysis software “ECG Buddy-LVD (model name EB-LVD-01)” has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
According to ALP, on the 6th (local time) the FDA issued a “Substantially Equivalent” determination for this product. The company explained that 510(k) is a premarket notification process in which the FDA confirms that a device is substantially equivalent to one that is already legally marketed.
According to the company, ECG Buddy-LVD is a software medical device that uses AI to analyze 12‑lead ECGs and identify findings associated with reduced left ventricular ejection fraction (LVEF). Left ventricular ejection fraction is the proportion of blood ejected from the left ventricle with each heartbeat and is an indicator of the heart’s pump function. The company stated that patients with a reduced LVEF are at higher risk of serious cardiac conditions such as heart failure.
ALP noted that echocardiography, the standard test for assessing left ventricular ejection fraction, requires specialized equipment and personnel, making it difficult to perform immediately in all clinical settings. In contrast, ECGs can be measured quickly and easily in medical institutions. For this reason, the company explained, AI analysis based on ECGs can serve as an auxiliary tool to help identify patients who may have impaired left ventricular function.
The company stated that this product provides reference information to help healthcare professionals recognize patients with suspected impaired cardiac function and consider follow‑up examinations. It emphasized that the tool does not replace diagnosis but rather supports clinical decision‑making by medical staff.
According to ALP, external validation research on the related technology analyzed more than 22,000 patient cases from the publicly available U.S. medical database MIMIC‑IV. The study was published in 2025 in the international journal “Clinical and Experimental Emergency Medicine.”
Kim Joonghee, CEO of ALP, said, “This FDA 510(k) clearance means that ECG Buddy has passed the first gateway to entering the U.S. market,” adding, “We will steadily demonstrate its value in U.S. clinical settings as well.”
ALP stated that it plans to work with U.S. medical institutions and local partners to promote the introduction of ECG Buddy-LVD.
Choi Yong-seok
AI-translated with ChatGPT. Provided as is; original Korean text prevails.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.